about Us
MS Pharma Consulting provides discovery ADME/DMPK
Non-clinical and clinical pharmacology, and nonclinical safety consulting services to support drug discovery, regulatory development and dossier registration.
Miquel Salvà – CEO & founder MS Pharma Consulting
MS Pharma Consulting is a scientific consulting firm that strives to develop innovative solutions to address the scientific, technical, and regulatory challenges confronting our clients. We apply sound science and novel approaches tailored to meet the specific needs of our clients, whether a rapid response or a comprehensive analysis is required.
Miquel Salvà, CEO & founder of MS Pharma Consulting, is a passionate scientist with more than 30 years of experience in discovery DMPK, nonclinical and clinical pharmacology, and nonclinical safety assessment of drugs in therapeutic fields such as allergy, gastrointestinal, CNS, respiratory diseases, dermatology and oncology.
Miquel led Almirall’s discovery, nonclinical and clinical DMPK team for 23 years and the nonclinical safety team for over 16 years. Then, he continued his career in the integrated drug discovery team of Syngene International as Executive Director of DMPK. During this time, he has participated in the discovery, development and regulatory approval of several drugs including the antimigraine almotriptan, the long-acting antimuscarinic drug aclidinium bromide, dimethylfumarate for psoriasis, the anti-IL23 monoclonal antibody tildrakizumab for psoriasis and the actinic keratosis topical drug tirbanibulin.
Añade aquí tu texto de cabecera
Our expertise includes the areas of nonclinical and clinical DMPK and nonclinical safety covering a broad range of indications.
1 – Pharmacokinetics, Drug Metabolism and Nonclinical Safety in Drug Discovery and Development: delineation of drug discovery/development strategies, study monitoring and execution, and data integration into the project.
2 – Regulatory Science: preparation of Preclinical Development and Clinical Pharmacology regulatory submissions and medicines agencies interactions. Support to worldwide regulatory interactions for initiation of clinical trials (INDs, CTAs, etc) and product registration (NDA, BLA, MAA, CTD, etc). Regulatory Agency interphase for DMPK and nonclinical safety meetings.
- Preclinical development and clinical DMPK support for broad range of therapeutic areas including allergy, gastrointestinal, CNS, respiratory diseases, dermatology and cancer.
- Develop and manage effective strategies for resolving preclinical DMPK, nonclinical and clinical DMPK and nonclinical safety issues for Discovery and Development projects.
- Provide discovery and development DMPK and nonclinical safety assessments for business development and licensing opportunities.